Trial Profile
A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Acronyms CARE1; CrisADe CARE 1
- Sponsors Pfizer
- 22 Feb 2023 Results of an analysis impact of crisaborole on sleep outcomes in pediatric patients atopic dermatitis from three clinical studies: CORE-1, CORE-2 and CrisADe CARE 1 study published in the Dermatology and Therapy
- 25 Apr 2021 Results of post-hoc analysis assessing the efficacy and safety of crisaborole by body region in infants presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 24 Mar 2020 Results published in the American Journal of Clinical Dermatology